Teva presents positive data from Ajovy pediatric study
by
Contributor since / Followers
Contributor since / Followers
15 hours ago
JHVEPhoto/iStock Editorial via Getty Images
Teva (NYSE:TEVA) presented positive data from a Phase 3 study of its drug Ajovy in the prevention of episodic migraine in children.
The Israeli drugmaker said the study showed Ajovy significantly reduced the monthly migraine days and monthly headache days